会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Synthesis of selective androgen receptor modulators
    • 选择性雄激素受体调节剂的合成
    • US07759520B2
    • 2010-07-20
    • US11062752
    • 2005-02-23
    • James T. DaltonDuane D. MillerDonghua YinYali He
    • James T. DaltonDuane D. MillerDonghua YinYali He
    • C07C233/05
    • C07C231/12C07C235/24
    • The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.
    • 本发明涉及一种用于制备新型雄激素受体靶向剂(ARTA)的合成方法,其表现出雄激素受体的非甾族化合物的雄激素和合成代谢活性。 这些药剂定义了一种新的选择性雄激素受体调节剂(SARM)的化合物亚类,它们可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防慢性肌肉消瘦; e)降低前列腺癌的发生率,停止或导致消退; f)口服雄激素替代和/或其他临床治疗和/或诊断领域。 本发明的方法适用于大规模制备,因为所有步骤都产生高纯度的化合物,因此避免了复杂的纯化方法,从而降低产率。 因此,本发明提供了可用于工业大规模合成的非甾体激动剂化合物的合成方法,并以高产率提供高纯度产品。
    • 3. 发明申请
    • SELECTIVE ANDROGEN RECEPTOR MODULATORS
    • 选择性雄激素受体调节剂
    • US20090264534A1
    • 2009-10-22
    • US12420731
    • 2009-04-08
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • A61K31/165C07C237/14A61P5/00
    • C07C235/24A61K31/165
    • The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen replacement and/or other clinical therapeutic and/or diagnostic areas.
    • 本发明涉及雄激素和合成代谢活性的雄激素受体靶向剂(ARTA),其是雄激素受体的非甾体配体。 选择性雄激素受体调节剂(SARM)可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防慢性肌肉消瘦; e)降低前列腺癌的发生率,停止或导致消退; f)口服雄激素替代物和/或其他临床治疗和/或诊断领域。
    • 4. 发明授权
    • Selective androgen receptor modulators
    • 选择性雄激素受体调节剂
    • US07518013B2
    • 2009-04-14
    • US11353225
    • 2006-02-14
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • C07C255/49A61K31/275
    • C07C255/60
    • The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.
    • 本发明涉及雄激素和合成代谢活性的雄激素受体靶向剂(ARTA),其是雄激素受体的非甾体配体。 选择性雄激素受体调节剂(SARM)可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防慢性肌肉消瘦; e)降低前列腺癌的发生率,停止或导致消退; f)口服雄激素替代和/或其他临床治疗和/或诊断领域。
    • 5. 发明授权
    • Selective androgen receptor modulators
    • 选择性雄激素受体调节剂
    • US07205437B2
    • 2007-04-17
    • US11125159
    • 2005-05-10
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • C07C233/05C07C255/00
    • C07C235/24
    • The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.
    • 本发明涉及雄激素和合成代谢活性的雄激素受体靶向剂(ARTA),其是雄激素受体的非甾体配体。 选择性雄激素受体调节剂(SARM)可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防慢性肌肉消瘦; e)降低前列腺癌的发生率,停止或导致消退; f)口服雄激素替代和/或其他临床治疗和/或诊断领域。
    • 6. 发明申请
    • SELECTIVE ANDROGEN RECEPTOR MODULATORS
    • 选择性雄激素受体调节剂
    • US20060287547A1
    • 2006-12-21
    • US11125159
    • 2005-05-10
    • James DaltonDuane MillerYali HeDonghua Yin
    • James DaltonDuane MillerYali HeDonghua Yin
    • C07C237/32C07C255/56
    • C07C235/24
    • The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.
    • 本发明涉及雄激素和合成代谢活性的雄激素受体靶向剂(ARTA),其是雄激素受体的非甾体配体。 选择性雄激素受体调节剂(SARM)可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防慢性肌肉消瘦; e)降低前列腺癌的发生率,停止或导致消退; f)口服雄激素替代和/或其他临床治疗和/或诊断领域。
    • 10. 发明授权
    • Synthesis of selective androgen receptor modulators
    • 选择性雄激素受体调节剂的合成
    • US06995284B2
    • 2006-02-07
    • US10277108
    • 2002-10-22
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • James T. DaltonDuane D. MillerYali HeDonghua Yin
    • C07C233/05C07C231/12
    • C07D215/227A61K31/167A61K31/404A61K31/4706A61K31/661C07C235/24C07D209/08C07D271/12G01N30/7233G01N33/5438G01N33/74G01N2030/8813
    • The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.
    • 本发明涉及一种用于制备新型雄激素受体靶向剂(ARTA)的合成方法,其表现出雄激素受体的非甾族化合物的雄激素和合成代谢活性。 这些药剂定义了一种新的选择性雄激素受体调节剂(SARM)的化合物亚类,它们可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防慢性肌肉消瘦; e)降低前列腺癌的发生率,停止或导致消退; f)口服雄激素替代和/或其他临床治疗和/或诊断领域。 本发明的方法适用于大规模制备,因为所有步骤都产生高纯度的化合物,因此避免了复杂的纯化方法,从而降低产率。 因此,本发明提供了可用于工业大规模合成的非甾体激动剂化合物的合成方法,并以高产率提供高纯度产品。